Business
Research & Co-Development Collaborations Update
Research & Co-Development Collaborations Update.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 9259P Sareum Holdings PLC 24 February 2016 \n\n\n\n\n\n(AIM: SAR)\n\n\n24 February 2016\n\n\n\n\nSAREUM HOLDINGS PLC(\"Sareum\" or the \"Company\") \nResearch & Co-Development Collaborations Update\nSareum (AIM: SAR), the specialist cancer drug discovery and development business, reports positive progress with its cancer and autoimmune disease research programmes and announces the following updates on each of these programmes.\nDr Tim Mitchell, CEO of Sareum, said: \"Good progress has been made in all our lead programmes. This year will focus on the start of CHK1 clinical trials, progressing toxicology studies for Aurora+FLT3, and evaluating lead compounds from our TYK2 programme in relevant autoimmune and cancer disease models.\"\nCheckpoint Kinase 1 (CHK1) \nTargeting lung, pancreatic and other cancers, in partnership with the CRT Pioneer Fund\nPreclinical toxicology studies to determine initial doses to be used in Phase I clinical trials were completed during 2015, as was the production of a GMP (Good Manufacturing Practice) batch of the drug candidate, CCT245737, for administration to patients in these trials. \nApplications for two clinical trials in cancer patients were made to MHRA, the UK regulator, in January 2015 and trials are expected to commence shortly after approvals are obtained. One trial plans to examine CCT245737 in combination with other standard-of-care chemotherapies, ultimately targeting lung and pancreatic cancers. The second trial plans to assess CCT245737 as a single anti-cancer agent in patients with various cancer types.\nThe evaluation of CCT245737 in the two planned trials will be facilitated by the use of biochemical tests, known as biomarkers. These biomarkers can demonstrate that the candidate drug is performing as expected, by quantitatively measuring the degree of CHK1 inhibition in cancer patients. A novel biomarker strategy has been developed by scientists at the Institute of Cancer Research, funded by the Sareum and CRT Pioneer Fund co-development partnership, which is intended for use in these trials. \nAurora+FLT3 \nTargeting AML and other blood cancers, in partnership with HMUBEC\nThe work is being performed at two Chinese CROs with strong experience of preclinical development to the standards required by the China FDA and US FDA. This preclin...